



SUPPLEMENT APPROVAL

December 9, 2021

Diagast
Attention: Ms. Sonia Lecce
NAMSA
400 Highway 169 South, Suite 500
Minneapolis, MN 55426

Dear Ms. Lecce:

We have approved your requests submitted June 30, 2021, received July 9, 2021, to supplement your Biologics License Applications (BLAs) submitted under section 351(a) of the Public Health Service Act to add warning and precaution related recommendations to the package inserts for the following products:

STN Name of Biological Products

BL 125615/8*	Blood Grouping Reagent, Anti-A (Murine Monoclonal)
BL 125616/8	Anti-Human Globulin (Murine Monoclonal)
BL 125617/8	Blood Grouping Reagent, Anti-A, B (Murine Monoclonal)
BL 125618/8	Blood Grouping Reagent, Anti-s (Human/Murine Monoclonal)(IgG)
BL 125619/8	Blood Grouping Reagent, Anti-B (Murine Monoclonal)
BL 125620/8	Blood Grouping Reagent, Anti-D (Human/Murine Monoclonal)
BL 125621/12	Blood Grouping Reagent, Anti-D (Human/Murine Monoclonal)
BL 125622/8	Blood Grouping Reagent, Anti-C (Human/Murine Monoclonal)
BL 125623/8	Blood Grouping Reagent, Anti-E (Human/Murine Monoclonal)
BL 125624/8	Blood Grouping Reagent, Anti-c (Human/Murine Monoclonal)
BL 125625/8	Blood Grouping Reagent, Anti-e (Human/Murine Monoclonal)
BL 125626/8	Blood Grouping Reagent, Anti-K (Human/Murine Monoclonal)
BL 125627/8	Blood Grouping Reagent, Anti-P ₁ (Murine Monoclonal)
BL 125628/8	Blood Grouping Reagent, Anti-Fy ^a (Human/Murine Monoclonal)(IgG)

BL 125629/8	Blood Grouping Reagent, Anti-D (Human/Murine Monoclonal)(IgG)
BL 125630/8	Blood Grouping Reagent, Anti-Fy ^b (Human/Murine Monoclonal)
BL 125631/8	Blood Grouping Reagent, Anti-Jk ^a (Human/Murine Monoclonal)
BL 125632/8	Blood Grouping Reagent, Anti-Jk ^b (Human/Murine Monoclonal)
BL 125633/8	Blood Grouping Reagent, Anti-M (Murine Monoclonal)(IgG)
BL 125634/8	Blood Grouping Reagent, Anti-S (Human/Murine Monoclonal)(IgG)
BL 125635/8	Blood Grouping Reagent, Anti-Le ^a (Murine Monoclonal)
BL 125636/8	Blood Grouping Reagent, Anti-Le ^b (Murine Monoclonal)

We hereby approve the draft package insert labeling submitted under amendment #1, dated September 9, 2021. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at <http://www.fda.gov/udi>.

Please submit all final printed labeling as PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch.

Please note:

In response to the COVID-19 public health emergency, CBER's Document Control Center (DCC) does not have staff on site to accept packages. Device submissions for CBER regulated devices may still be submitted electronically using the Electronic Submissions Gateway (ESG) (under 10GB) in accordance with final industry guidance, eCOPY Program for Medical Devices Submissions found at <https://www.fda.gov/media/83522/download>. CBER strongly encourages sending submissions through the ESG, FDA's preferred secure method of transmission. Instructions for setting up an ESG account can be found at <https://www.fda.gov/industry/electronic-submissions-gateway>.

Submissions may also be submitted electronically via email (under 150MB) at CBERDCC_eMailSub@fda.hhs.gov. We will accept submissions through this email option only during the COVID-19 public health emergency. For additional information regarding CBER operations during this public health emergency, please see the CBER COVID -19 CBER Regulated Biologics page found at <https://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics>.

Please submit an amendment to all pending supplemental applications for these BLAs that include revised labeling incorporating a revised content of labeling that includes these changes.

We will include information contained in the above-referenced supplements in your BLA files.

Sincerely,

Orieji Illoh, MD
Director
Division of Blood Components and Devices
Office of Blood Research and Review
Center for Biologics Evaluation and Research